Guardant Health, Inc. $GH Shares Sold by TD Asset Management Inc

TD Asset Management Inc cut its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 4.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 181,048 shares of the company’s stock after selling 7,762 shares during the quarter. TD Asset Management Inc owned 0.14% of Guardant Health worth $18,492,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of GH. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health during the fourth quarter worth $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth $35,000. Finally, First Pacific Financial acquired a new stake in shares of Guardant Health during the fourth quarter worth $43,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider John G. Saia sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the transaction, the insider owned 45,950 shares in the company, valued at $4,894,134.50. This trade represents a 30.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 24,406 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total value of $2,896,260.02. Following the completion of the transaction, the insider owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. This represents a 28.90% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 350,238 shares of company stock worth $38,538,372. Insiders own 5.60% of the company’s stock.

Analysts Set New Price Targets

GH has been the subject of several recent research reports. Piper Sandler set a $127.00 price target on Guardant Health in a report on Thursday, May 21st. Raymond James Financial reiterated an “outperform” rating and issued a $129.00 price objective on shares of Guardant Health in a research report on Monday, February 23rd. Citigroup boosted their target price on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Robert W. Baird started coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an “outperform” rating and a $120.00 price target on the stock. Finally, BTIG Research set a $160.00 price target on shares of Guardant Health and gave the company a “buy” rating in a report on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $137.80.

Guardant Health Price Performance

Shares of GH opened at $125.61 on Monday. The company has a 50-day simple moving average of $99.39 and a 200-day simple moving average of $101.12. The company has a market capitalization of $16.66 billion, a PE ratio of -37.05 and a beta of 1.61. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $134.28.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.